EXACT Therapeutics: Warrants exercise by leading shareholders and primary insiders
Oslo, Norway, 5 February 2026. Reference is made to the stock exchange announcement by EXACT Therapeutics AS (the "Company", Euronext Growth ticker: EXTX), a clinical-stage precision medicine company, earlier today on 5 February 2026, confirming that GE Medical Holdings AB (“GEMH”) will exercise of all of its 26,973,169 warrants.
The Company is pleased to announce that the following major shareholders and primary insiders today have confirmed that they will exercise all of their warrants, as follows:
Investinor Direkte AS, a close associate of board member Ann-Tove Kongsnes: 4,875,920 warrants
Helene Sundt AS, a close associate of board member Leiv Askvig: 2,050,577 warrants
Sundt AS, a close associate of board member Leiv Askvig: 420,396 warrants
Basen Kapital AS, a close associate of board member Leiv Askvig: 87,107 warrants
Anders Wold, chair of the Company: 69,685 warrants
Canica AS: 3,273,334 warrants
The exercise of the above-mentioned warrants, combined with the warrants exercised by GEMH, accounts for 75% of the total warrants issued in conjunction with the private placement completed in December 2024, corresponding to gross proceeds of NOK 46 million.
The remaining warrants holders may exercise their warrants within 21 February 2026. Updates on the warrant exercise will follow in due course. As soon as the Company has confirmation from the remaining warrants holders on whether they will exercise their warrants, the Company will call for an extraordinary general meeting to ensure that the relevant number of new shares are issued.
Further, please find attached an updated corporate presentation which may also be found in the Investors section of the Company’s webpage.